3 research outputs found
Density dependence in the spatial behaviour of anchovy and sardine across Mediterranean systems
A spatial indicator—the spreading area index—is used to describe anchovy and sardine spatial distribution in relation to biomass variation and to look for ecosystem differences within the Mediterranean basin. Specifically, the variation in the spreading area index in relation to biomass was examined for different areas of the Mediterranean Sea (i.e. Aegean Sea, western Adriatic Sea, Strait of Sicily, Gulf of Lion, and Spanish Mediterranean waters). In order to
capture the spatial variability of the population at different levels of fish density, acoustic survey data for the years of highest, lowest, and intermediate abundance were used. In a subsequent step standardized values of spreading area and biomass were estimated to allow comparisons.
Results showed pronounced area differences. A significant relationship was revealed in the case of anchovy for areas with extended continental shelf (i.e. Aegean Sea, Adriatic Sea, and Gulf of Lion), indicating an increase in biomass with an increase in the spreading area. No relationship was found for areas dominated by narrow continental shelf and strong currents (i.e. Spanish Mediterranean waters and the Strait of Sicily). With regard to sardine, an increase in biomass was followed by an increase in the spreading area when estimates from the Aegean Sea, the Adriatic Sea, and the Strait of Sicily were considered together. The relationship was even more Abstracts–Theme Session B 9 pronounced when analysis was limited to the Aegean Sea and the Strait of Sicily. No relationship was found for the Spanish Mediterranean waters and the Gulf of Lion. This clearly implies that spatial indicators should be integrated into ecosystem management, taking into account that they can be area‐ or ecosystem‐dependent
Identifying the potential habitat of anchovy Engraulis encrasicolus during different life stages in the Mediterranean Sea
Immunocompromised patients with acute respiratory distress syndrome : Secondary analysis of the LUNG SAFE database
The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge. Trial registration: ClinicalTrials.gov, NCT02010073. Registered on 12 December 2013